| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC1658 |
| Trial ID | NCT02935712 |
| Disease | Type 2 Diabetes Mellitus |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA |
| Treatment | AZD8601 |
| Co-treatment | Placebo |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM) |
| Year | 2016 |
| Country | Germany |
| Company sponsor | AstraZeneca |
| Other ID(s) | D9150C00001|2016-002316-40 |
| Cohort 1 | |||||||
|
|||||||